Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback (REGN)
If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Regeneron Pharmaceuticals, Inc. ( REGN ), the Tarrytown, New York headquartered Pharma company, reported its Q3 earnings yesterday. Its stock surged as revenues of 11.83 on a nor ...